To answer this question, we determined the effect of blocking CXCL9/CXCL10-CXCR3 interaction on development of AIP by administration of a neutralizing antibody (Ab) against CXCR3 or control Ab at the time of each poly(I:C) injection. This evidence concerns the gene CXCR3 and autoimmune pancreatitis.